AR132641A1 - Anticuerpos biespecíficos anti-pseudomonas con regiones fc modificadas y métodos de uso de los mismos - Google Patents
Anticuerpos biespecíficos anti-pseudomonas con regiones fc modificadas y métodos de uso de los mismosInfo
- Publication number
- AR132641A1 AR132641A1 ARP240101175A ARP240101175A AR132641A1 AR 132641 A1 AR132641 A1 AR 132641A1 AR P240101175 A ARP240101175 A AR P240101175A AR P240101175 A ARP240101175 A AR P240101175A AR 132641 A1 AR132641 A1 AR 132641A1
- Authority
- AR
- Argentina
- Prior art keywords
- region
- bispecific antibody
- antibody
- modified
- histidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1214—Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a un anticuerpo biespecífico que se une específicamente a la proteína PcrV de Pseudomonas aeruginosa y al exopolisacárido Psl y que comprende una región Fc modificada. Dichos anticuerpos biespecíficos pueden, por ejemplo, tener una semivida aumentada y una agregación disminuida en el proceso de fabricación sin una potencia disminuida frente a Pseudomonas, en comparación con los anticuerpos biespecíficos sin la región Fc modificada. Reivindicación 1: Un anticuerpo biespecífico que se une específicamente a la proteína PcrV de Pseudomonas aeruginosa y al exopolisacárido Psl, en donde el anticuerpo comprende una región Fc de IgG modificada, donde la región Fc de IgG modificada comprende sustituciones de aminoácidos en dos o más de las posiciones 432 a 437, numeradas de acuerdo con el índice de numeración EU de Kabat, con respecto a una región Fc de IgG de tipo salvaje; en donde (i) las posiciones 432 y 437 se sustituyen cada una con cisteína; (ii) la posición 433 es histidina o está sustituida con arginina, prolina, treonina, lisina, serina, alanina, metionina o asparagina; (iii) la posición 434 es asparagina o está sustituida con arginina, triptófano, histidina, fenilalanina, tirosina, serina, metionina o treonina; (iv) la posición 435 es histidina; y (v) la posición 436 es tirosina o fenilalanina o está sustituida por leucina, arginina, isoleucina, lisina, metionina, valina, histidina, serina o treonina; y en donde el anticuerpo tiene una semivida aumentada en comparación con la semivida de un anticuerpo correspondiente que tenga la región Fc de IgG de tipo salvaje. Reivindicación 43: Un polinucleótido aislado que comprende una molécula de ácido nucleico que codifica la cadena pesada del anticuerpo biespecífico de una cualquiera de las reivindicaciones 1 - 42. Reivindicación 45: Un vector que comprende el polinucleótido de la reivindicación 43 o 44. Reivindicación 46: Una célula hospedadora que comprende (i) el polinucleótido de la reivindicación 43 o 44, o (ii) el vector de la reivindicación 45. Reivindicación 47: Un método para producir un anticuerpo biespecífico, en donde el método comprende cultivar la célula hospedadora de la reivindicación 46 y, opcionalmente, aislar el anticuerpo biespecífico. Reivindicación 48: Un anticuerpo biespecífico producido por el método de la reivindicación 47. Reivindicación 49: Una composición que comprende el anticuerpo biespecífico de una cualquiera de las reivindicaciones 1 - 42 o 48, y un portador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363501036P | 2023-05-09 | 2023-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132641A1 true AR132641A1 (es) | 2025-07-16 |
Family
ID=91082227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101175A AR132641A1 (es) | 2023-05-09 | 2024-05-08 | Anticuerpos biespecíficos anti-pseudomonas con regiones fc modificadas y métodos de uso de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4709750A1 (es) |
| JP (1) | JP2026518603A (es) |
| KR (1) | KR20260008784A (es) |
| CN (2) | CN121057745A (es) |
| AR (1) | AR132641A1 (es) |
| AU (1) | AU2024269156A1 (es) |
| CL (1) | CL2025003427A1 (es) |
| CO (1) | CO2025016972A2 (es) |
| CR (1) | CR20250521A (es) |
| IL (1) | IL324469A (es) |
| MX (1) | MX2025013179A (es) |
| TW (1) | TW202509059A (es) |
| WO (1) | WO2024231440A1 (es) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| CA2326389C (en) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Novel cd19xcd3 specific polypeptides and uses thereof |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2013070615A1 (en) | 2011-11-07 | 2013-05-16 | Medlmmune, Llc. | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
| SG11201809778TA (en) * | 2016-05-05 | 2018-12-28 | Univ Pennsylvania | Dna antibody constructs for use against pseudomonas aeruginosa |
| MX2021000889A (es) * | 2018-07-24 | 2021-04-28 | Medimmune Llc | Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus. |
-
2024
- 2024-05-08 IL IL324469A patent/IL324469A/en unknown
- 2024-05-08 WO PCT/EP2024/062700 patent/WO2024231440A1/en not_active Ceased
- 2024-05-08 CN CN202480030566.0A patent/CN121057745A/zh active Pending
- 2024-05-08 EP EP24725776.9A patent/EP4709750A1/en active Pending
- 2024-05-08 CN CN202610595918.8A patent/CN122427291A/zh active Pending
- 2024-05-08 KR KR1020257040923A patent/KR20260008784A/ko active Pending
- 2024-05-08 AU AU2024269156A patent/AU2024269156A1/en active Pending
- 2024-05-08 JP JP2025564537A patent/JP2026518603A/ja active Pending
- 2024-05-08 TW TW113117049A patent/TW202509059A/zh unknown
- 2024-05-08 AR ARP240101175A patent/AR132641A1/es unknown
- 2024-05-08 CR CR20250521A patent/CR20250521A/es unknown
-
2025
- 2025-11-04 MX MX2025013179A patent/MX2025013179A/es unknown
- 2025-11-06 CL CL2025003427A patent/CL2025003427A1/es unknown
- 2025-12-04 CO CONC2025/0016972A patent/CO2025016972A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2025003427A1 (es) | 2026-02-13 |
| CO2025016972A2 (es) | 2025-12-19 |
| CN122427291A (zh) | 2026-07-21 |
| JP2026518603A (ja) | 2026-06-09 |
| KR20260008784A (ko) | 2026-01-16 |
| TW202509059A (zh) | 2025-03-01 |
| MX2025013179A (es) | 2025-12-01 |
| AU2024269156A1 (en) | 2026-01-08 |
| IL324469A (en) | 2026-01-01 |
| EP4709750A1 (en) | 2026-03-18 |
| CR20250521A (es) | 2026-01-14 |
| CN121057745A (zh) | 2025-12-02 |
| WO2024231440A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3129193C (en) | Anti-vegf protein compositions and methods for producing the same | |
| BR112022021397A2 (pt) | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma | |
| JP2015146822A5 (es) | ||
| PE20242297A1 (es) | Anticuerpo anti-ctla-4 | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR125212A1 (es) | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas | |
| PE20240086A1 (es) | Anticuerpos anti-cd122 y usos de estos | |
| RU2010116208A (ru) | Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr | |
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| CL2024002975A1 (es) | Anticuerpo biespecífico anti-tigit y anti-pvrig, composición farmacéutica del mismo, y uso del mismo | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| CN109415438A (zh) | 一类抗cd20靶向抗体及用途技术领域 | |
| CL2018003072A1 (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| CN114556104A (zh) | 用于表征宿主细胞蛋白的方法 | |
| AR129991A1 (es) | Anticuerpos que se unen a la pad4 humana y usos de los mismos | |
| CO2025004790A2 (es) | Anticuerpo anti-il-1r3 humanizado y métodos de uso | |
| AR123728A1 (es) | Anticuerpos cd1a y su uso | |
| PE20240110A1 (es) | Variantes de anticuerpos felinos | |
| RU2021128024A (ru) | Способы культивирования клеток | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| Bolen et al. | Separation of neutralizing and hemagglutination-inhibiting antibody activities and specificity of antisera to sodium dodecyl sulfate-derived polypeptides of polyoma virions | |
| PE20231858A1 (es) | Anticuerpo multiespecifico | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| CA3007018A1 (en) | Cgrp antibodies and uses thereof |